Organ transplantation candidates who are seronegative for cytomegalovirus (CMV) and receive a transplant from a donor who is CMV-seropositive (CMV D+/R– transplantation) are the population at ...

The CMV genome is composed of lineal ... These mechanisms prompt to a latent infection that may be reactivated in transplant recipients. The purpose of this review is to conduct a critical ...

Encouraging results from earlier pilot studies suggest that vaccinating stem cell donors with Triplex may convey protective CMV-specific T cell immunity to transplant recipients, potentially ...

Fortress Biotech and its subsidiary Helocyte have announced the dosing of the first subject in a multi-centre Phase II trial ...

CMV is one of the most common and serious post-transplant infections with an estimated incidence rate of between 16% and 56% in solid organ transplants, and 30% to 70% in HSCT procedures.

A new study from the Hong Kong Children's Hospital reveals critical insights into the infection risks associated with ...

Absence of identified large CMV- or EBV- specific clonal expansions ... some protection from common pathogens in the early post-transplant period, but their presence is associated with graft ...

Fortress Biotech (FBIO) and its majority-owned subsidiary, Helocyte, announced that the first patient was dosed in a ...

Triplex is expected to trigger a CMV-specific immune response in the donor, which is then transferred to the transplant recipient. The initial Phase II trial builds on the findings from the Phase ...

Due to the rarity of CMV, long-term follow-up is essential to understand recurrence and progression-free survival. Transplant recipients are at higher risk for complications and death from CMV.